RegeneRx Biopharmaceuticals (RGRX) News Today $0.0014 0.00 (0.00%) As of 04/3/2025 Add Compare Share Share Headlines Stock AnalysisChartFinancialsSEC FilingsShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period EIGRQ Eiger BioPharmaceuticals, Inc.July 19, 2024 | seekingalpha.comRegenerx Biopharmaceuticals Inc RGRXDNovember 5, 2023 | morningstar.comRegenerx Biopharm In (RGRXD)October 31, 2023 | investing.comLIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater ChinaSeptember 21, 2023 | businesswire.comRGRX RegeneRx Biopharmaceuticals, Inc.August 26, 2023 | seekingalpha.comRegeneRx Effects Reverse Stock Split and Terminates SEC Reporting ObligationsAugust 15, 2023 | finance.yahoo.comRegeneRx Receives Stockholder Approval for Reverse Stock SplitAugust 8, 2023 | finance.yahoo.comRegeneRx To Extend Consent Solicitation VoteAugust 1, 2023 | finance.yahoo.comBristol-Myers to Split Off Mead JohnsonJuly 7, 2023 | thestreet.comPlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage InitiationMay 19, 2023 | thestreet.comFirst Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259April 13, 2023 | finance.yahoo.comBiopharmaceutical (Biopharma) Aseptic Filling Machine Market Drivers, Risks, Potential Outcomes, and Major Segments for 2030April 7, 2023 | marketwatch.comBiopharmaceutical Third Party Logistics (3PL) Market | 2023-2029April 7, 2023 | marketwatch.com2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029March 1, 2023 | marketwatch.comBiopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028February 25, 2023 | marketwatch.comBiopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027February 24, 2023 | marketwatch.comBiopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)February 12, 2023 | finance.yahoo.comThymosin Beta 4 Research Leads Toward Potential Future Anti-aging TherapyJanuary 31, 2023 | finance.yahoo.com$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are BuyingJanuary 27, 2023 | markets.businessinsider.comBiopharmaceutical Processing Equipment and Consumable Market Size in 2023 Share & Comprehensive Analysis till 2028 [ NEW REPORT ]January 18, 2023 | marketwatch.comBiopharmaceutical CMO & CRO Market Size 2023 with End-user Industries, Segments Covered in the ReportJanuary 17, 2023 | marketwatch.comPublication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic KeratopathyJanuary 3, 2023 | finance.yahoo.comBiopharmaceutical Contract Manufacturing Market, 2035 - Shift from One-time Contracts to Strategic PartnershipsNovember 18, 2022 | finance.yahoo.comRegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye DiseaseOctober 24, 2022 | finance.yahoo.comClover Biopharmaceuticals Ltd (2197)September 30, 2022 | investing.comRegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)September 27, 2022 | finance.yahoo.comRegeneRx Issues 2022 Letter To StockholdersAugust 22, 2022 | finance.yahoo.comRegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic KeratitisJuly 18, 2022 | finance.yahoo.comRegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259June 22, 2022 | finance.yahoo.comTβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the CorneaMay 4, 2022 | finance.yahoo.comRegeneRx Consultant to Receive Prestigious Award for Contributions in Field of HealthFebruary 11, 2022 | finance.yahoo.comRGRX Real-Time QuotesFebruary 7, 2022 | nasdaq.comResearchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol InjuryJanuary 25, 2022 | finance.yahoo.comRGRX After-Hours QuotesJanuary 20, 2022 | nasdaq.comMicrocap RegeneRx surges 17% on regulatory development for ophthalmic candidateJanuary 12, 2022 | seekingalpha.comRegeneRx Publishes Regulatory Update on RGN-259January 12, 2022 | stockhouse.comRegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022December 17, 2021 | finance.yahoo.comRegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye SyndromeNovember 29, 2021 | finance.yahoo.comClinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association MeetingOctober 29, 2021 | finance.yahoo.comResearchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with SepsisOctober 6, 2021 | finance.yahoo.comNew Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's DiseaseOctober 5, 2021 | finance.yahoo.comBeyond Meat's plant-based 'chicken' tenders are coming to grocery storesSeptember 30, 2021 | yahoo.comRegeneRx Licensee Acquired by Korean Biopharmaceutical GroupSeptember 27, 2021 | finance.yahoo.comRegenerx Biopharmaceuticals Inc RGRXJuly 25, 2021 | morningstar.comRegeneRx Issues Letter To StockholdersJuly 22, 2021 | finance.yahoo.com Remove Ads Get RegeneRx Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address RGRX Media Mentions By Week RGRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGRX News Sentiment▼0.000.62▲Average Medical News Sentiment RGRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGRX Articles This Week▼00▲RGRX Articles Average Week Remove Ads Get RegeneRx Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMV News PaxMedica News Sienna Biopharmaceuticals News eFFECTOR Therapeutics News 4Front Ventures News Algernon Pharmaceuticals News Allstar Health Brands News Anew Medical News Arno Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RGRX) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RegeneRx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RegeneRx Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
